| dc.description.abstract | Furosemide is a loop diuretic that has been around for a long time. Furosemide has been approved by the Food and Drug Administration (FDA) to treat conditions characterized by volume overload and edema as a result of congestive heart failure exacerbation, liver failure, or renal failure, including the nephrotic syndrome. Historically, there has been a scarcity of information on female pharmacokinetics and the possibility of gender differences in the relationships between dose and efficacy or dose and adverse drug reactions. Only a few studies were able to clearly identify clinically significant gender effects in terms of pharmacodynamics. Because females make up roughly half of any species' population, it is appropriate to consider the effect of sex on drug pharmacokinetics and pharmacodynamics, of study to show gender difference in Pharmacodynamics of furosemide in human. there was no statistically significant difference between male and female subjects in terms of urine flow rate, sodium, and potassium excretion rates along the course of treatments, there was no statistically significant difference between male and female subjects in terms of urine flow rate, sodium, and potassium excretion rates along the course of treatments | en_US |
